BLESS fluctuates 145.5% in 24 hours: Abnormal trading volume and on-chain activity drive speculative pump
Bitget Pulse2026/04/14 22:03Volatility Overview
In the past 24 hours, BLESS price rebounded from a low of $0.0152 to a high of $0.0373, currently quoted at $0.0185, with a price fluctuation reaching 145.5%. Trading volume surged to $128 million, the market cap is approximately $35.7 million, and liquidity has improved significantly.
Brief Analysis of the Abnormal Movement
- Unusually high trading volume: 24-hour volume soared over 140% to exceed $100 million, driving the price to rally rapidly from a $0.0128 low, indicating strong speculative buying.
- Active on-chain activity signals: Monitoring shows abnormal increases in on-chain transactions, supporting the price pump, but concerns about liquidity remain.
- Exchange listing: WEEX added the BLESS/USDT trading pair on April 14, 2026, improving accessibility.
Market Opinions & Outlook
Mainstream sentiment in the community is bullish, with traders on X viewing this as a strong pump and expecting another rally after a pullback (targeting $0.022-$0.026). However, there are widespread warnings of FOMO risks and potential liquidity sweep traps, suggesting to wait for $0.0176 support confirmation before entering. If trading volume falls below $15 million, the outlook may turn weak.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for information reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PURR stock hits record $14.15 as Hyperliquid revenue tops $718 million
From Lowering Blood Sugar and Weight Loss to Cardiovascular Protection! Mounjaro Achieves "Cardiometabolic Leap," Lilly (LLY.US) Opens GLP-1's Second Growth Curve
Eli Lilly's diabetes drug Mounjaro has received approval in the United States for reducing the risk of serious cardiovascular disease. The U.S. Food and Drug Administration has approved Mounjaro for lowering cardiovascular risk in adults with type 2 diabetes who have established heart disease.

Altcoin XRP Shows Clear Potential for $15 ATH Target, When Will the Massive Surge Occur?

EGRAG Crypto sees $7 XRP price if market cap reaches $500 billion by 2029